市場調査レポート
商品コード
1153816
幹細胞バンクの世界市場-2022-2029Global Stem Cell Banking Market - 2022-2029 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
幹細胞バンクの世界市場-2022-2029 |
出版日: 2022年11月15日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 即日から翌営業日
|
世界の幹細胞バンク市場は、2021年に50億1563万米ドルとなり、2029年には159億4792万米ドルに達し、予測期間中(2022年~2029年)に15.68%の年平均成長率で成長すると予測されています。
幹細胞は、細胞分裂によって無限に自己再生することができる未分化な細胞です。また、これらの細胞は、特定の機能を持つより成熟した細胞へと区別することができます。現在、幹細胞は80以上の厄介な病気の治療に使われています。幹細胞バンクは、幹細胞やその他の免疫系細胞を収集し、抽出し、凍結保存することで、将来の医療利用の可能性を探るものです。
これらの診断用製品の需要が増加している背景には、幹細胞の治療可能性に対する認識が高まっていることがあります。また、新規技術の進歩や研究開発費の増加も、市場の成長を後押しする要因となっています。これらすべての要因が市場成長の原動力となることが期待されます。
新規製品の発表数の増加や研究開発の高まりは、市場成長の原動力となるでしょう。
幹細胞バンクの世界市場は、主に幹細胞の治療可能性に対する認知度の向上により牽引されています。その他の市場成長の要因としては、新規の幹細胞保存、処理、保存技術の進歩が挙げられます。造血幹細胞移植の増加や、幹細胞を用いた研究への投資の増加は、幹細胞バンクをさらに推進します。新興国、主要疾患の世界の負担の増加、新生児の数の多さ、GDP成長の伸び、可処分所得は、主要プレイヤーにとって市場機会として作用します。例えば、2021年9月、幹細胞バンクと診断ソリューションのプロバイダーであるLifeCellは、同社の新規治療法であるMesocelが、インドのDGCI(Drug Controller General)からCOVID-19治療のための臨床試験の承認を取得したと発表しました。Mesocelは、提供された臍帯組織から得られた間葉系幹細胞から抽出されたものです。これにより、生命を脅かすCOVID-19肺炎や急性呼吸困難の患者さんの治療が可能になりました。臨床試験は2期に分けて実施する予定です。
様々な資金調達、斬新な技術の進歩、最新の革新的な製品の発売数が増加しており、これらの幹細胞バンクの高い需要に繋がっています。例えば、2021年3月、幹細胞バンクのLifeCell社は、LifeCellレジストリ内でマッチング可能な幹細胞ユニットの正確な品質と数に関する情報を提供するとして、バンク会員コミュニティにとって初のサービスであるStemMatchを開始しました。
幹細胞バンクにかかる高い治療費と運営費が市場の成長を妨げます。
しかし、幹細胞バンクの高い運用コストや幹細胞採取時の法的・倫理的問題、厳しい規制の枠組みや受容・認知度の低さが、市場の進展を阻害する可能性があります。これらの幹細胞治療にかかる費用の高さが、市場の成長を妨げています。幹細胞治療の革新的なクリニックであるDVC Stemによると、IRBの承認を受けた同社の間葉系幹細胞(MSC)プロトコルは、約25,000米ドルの費用がかかるとされています。
COVID-19の影響分析
パンデミックは、世界の財務的な期待、業務、危機対応戦略にマイナスの影響を及ぼしました。COVID-19の発生は、ヘルスケア産業に深刻な影響を及ぼしました。幹細胞バンク市場は、COVIDに注目が集まったためにすべての研究と臨床試験に影響が及び、莫大な損失を経験しました。しかし現在、市場参入企業は、研究市場を活用し、パンデミックに対抗するための最先端のアイテムを生み出すことで、長期的・短期的な成長戦略を変えつつあります。様々な取り組み、コラボレーション、合併が世界中で起こっており、市場の成長を後押ししています。例えば、2022年8月、臍帯血再生治療薬を製造するStemCyte社は、臍帯血幹細胞療法を用いたポストCOVID症候群の第2相臨床試験が米国食品医薬品局から承認を得たと発表しました。
The global stem cell banking market was valued at US$ 5,015.63 million in 2021 and is estimated to reach US$ 15,947.92 million by 2029, growing at a CAGR of 15.68% during the forecast period (2022-2029).
Stem cells are undifferentiated cells that can self-renew indefinitely through cell division. These cells can also be distinguished into more mature cells with specific functions. Currently, stem cells are used to treat more than 80 nasty diseases. Stem cell banking is collecting, extracting and storing by cryogenically freezing the stem cells and other immune system cells for potential future medical use.
The increasing demand for these diagnostic products is due to the growing awareness of the therapeutic potential of stem cells. Other factors aiding the market growth are the advancements in novel technologies and increasing research and development expenditure. All these factors are expected to drive market growth.
The global market for stem cell banking is primarily driven by the growing awareness of the therapeutic potential of stem cells. Other factors aiding the market growth are advancements in novel stem cell preservation, processing, and storage technologies. The rise in hematopoietic stem cell transplantation procedures and increasing investments in stem cell-based research further propel stem cell banking. Emerging countries, the rising global burden of major diseases, the large number of newborns, the growth in GDP growth, and disposable income act as market opportunities for key players. For instance, in Sep 2021, LifeCell, a stem cell bank and provider of diagnostic solutions, announced that its novel therapy, Mesocel, got approved for a clinical trial from DGCI, the Drug Controller General of India, for COVID-19 treatment. Mesocel is extracted from mesenchymal stem cells derived from the donated umbilical cord tissue. This can now be used to treat patients with life-threatening COVID-19 pneumonia or acute respiratory distress. The clinical trial will be conducted in 2 phases.
Various funding, novel technological advancements, and the number of the latest, innovative product launches are increasing, leading to the high demand for these stem cell banking. For instance, in Mar 2021, LifeCell, a stem cell banking company, launched StemMatch, a first-of-its-kind service for the banking members community as it gives information on the accurate quality and number of stem cell units that are matching available within the LifeCell registry.
However, the high operational costs of stem cell banking and legal and ethical issues during the collection of stem cells, along with stringent regulatory frameworks and lack of acceptance and awareness, may hinder the market progress. The high cost of these stem cell therapies is hindering the market growth. According to DVC Stem, an innovative clinic of stem cell therapy, its mesenchymal stem cell (MSC) protocol that is IRB approved costs around US$25,000.
The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The stem cell banking market has experienced huge losses due to COVID, as all the research and clinical trials got affected due to the diversion of attention toward COVID. But now, the market participants are changing their long-term and short-term growth strategies by utilizing the research market and creating cutting-edge items to combat the pandemic. Various initiatives, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in Aug 2022, StemCyte, a company manufacturing cord blood regenerative therapeutic, announced that Post-COVID Syndrome's Phase II clinical trial with the help of umbilical cord blood stem cell therapy got approved by U.S. Food and Drug Administration.
The umbilical cord-derived stem cells (UCSTs) segment is the highest market holder in the global stem cell banking market. Cord Blood is affluent in stem cells. Stem cells are developed in the bone marrow and differentiate into different blood cells, which are important in various therapies related to blood disorders, such as sickle cell disease. Umbilical cord blood can be used for gene therapy or transplantation as it's a hematopoietic stem cell source. Umbilical cord-derived mesenchymal stem cells can be used for inflammatory and immune disease therapy. These can be promising active substances for therapeutic product development as they have a few issues related to safety, availability and ethics.
Umbilical cord-derived stem cells dominate the market due to the rising birth rate and global chronic disease cases. According to the Centre for Disease Control and Prevention, in 2021, approximately 3,659,289 newborn cases were reported in the United States. The rising number of people suffering from blood-related disorders, regulatory approvals and growing technological advancements or research/clinical trial studies drive the market's growth. For instance, in May 2021, Cordlife Group Limited, 1st private cord blood bank in Singapore, entered into a partnership with SingHealth Duke-NUS Academic Medical Centre to test new technology that can increase blood-forming stem cells in number from stored umbilical cord blood that is stored in the first-in-man study in Singapore.
North America dominates the global stem cell banking market, primarily attributed to the rising prevalence of chronic ailments such as leukemia, thalassemia, diabetes, autism and many more due to changing environments worldwide, established healthcare infrastructure, and higher investment in R&D activities contribute to North America's rapid share growth. Moreover, its broad base patient population also contributes to the growth of its share. According to the American Cancer Society, in 2022, Around 60.650 estimated novel leukemia cases will occur, out of which 24,000 deaths will occur in the United States.
Moreover, the growing number of product launches is responsible for the market's growth. Other factors, such as the high spending of GDP on healthcare, stimulate the market's growth. Many key developments, technological advancements, collaborations and agreements are taking place in this region. For instance, in Feb 2021, American CryoStem Corporation, a biotechnology company at the clinical stage working on autologous cellular therapies, announced its agreement with BioTherapeutics Labs Corp., a company manufacturing umbilical cord tissues that's also FDA-registered.
The stem cell banking market is highly competitive with local and global companies' presence. Stem Cyte Inc., Cryo-cell International, American CryoStem Corporation, ViaCord, Cord Blood Registry Systems, SmartCells, Inc. (Merck), LifeCell International Pvt. Ltd., Cryoviva Biotech Pvt. Ltd, Cordlife Group Ltd., Transcell Biolife Pvt. Ltd and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in Feb 2021, Cryo-Cell International Inc, a private cord blood bank that separates and stores stem cells, announced a collaboration with Duke University. With this agreement, Cryo-Cell gets the rights to regulatory data and proprietary processes developed at Duke related to cord tissue or blood.
Overview:
StemCyte Inc. is a company involved in blood regenerative therapeutics. It provides family storage and public donations and is the only for-profit company that the US Department of HHS contracts. It was established in 1997 and is headquartered in California, United States.
MaxCell: MaxCell is StemCyte's proprietary processing method that retains the stem cells in higher volume. It preserves more total nucleated cells than other standard processing procedures, improving engraftment chances.
Key Development: In May 2022, StemCyte, a blood regenerative therapeutics company, announced renewing its agreement with California Umbilical Cord Blood Collection Program. StemCyte helped raise collections at hospitals in Southern California by extending the cord blood collection hours.
The global stem cell banking market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.
LIST NOT EXHAUSTIVE